Hila Pharma

Company Overview

Snapshot

Founded in November 2018 by Tsvi Dahan and Meir Dahan, Hila Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing products for molecular imaging. In September 2020, the company's Israeli innovation claimed to kill over 99% of airborne viruses.

Business overview

Hila Pharma develops products for molecular imaging to enable precise diagnoses and improved therapy planning, with a focus on nuclear medicine. The company trades a broad range of products for both diagnostic and therapeutic purposes, including SPECT and PET diagnostic products, MRI contrast agents, and nuclear therapeutic materials like LU-177. Hila Pharma serves the healthcare and life sciences, industrial manufacturing, education, government, and transportation sectors, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices, Diagnostics Devices, and Pharma & Medical Biotechnology.

Strategic signal

In September 2020, Hila Pharma's Israeli innovation, ProtectAir, claimed to kill over 99% of airborne viruses. This development highlights the company's potential to address critical public health challenges beyond its core molecular imaging focus, signaling a strategic diversification into broader health and safety solutions that could attract interest from various market segments, including government and public transportation.

Company Intelligence Q&A

What is Hila Pharma's primary focus?

Hila Pharma is focused on developing products for molecular imaging to facilitate precise diagnoses and enhance therapy planning, particularly within the field of nuclear medicine.

Who founded Hila Pharma?

Hila Pharma was founded by Tsvi Dahan and Meir Dahan in November 2018.

What types of products does Hila Pharma offer?

Hila Pharma offers a range of diagnostic and therapeutic products, including SPECT and PET diagnostic products, MRI contrast agents, and nuclear therapeutic materials such as LU-177.

What was a notable development for Hila Pharma in 2020?

In September 2020, Hila Pharma's Israeli innovation, ProtectAir, claimed to kill over 99% of airborne viruses, showcasing the company's capabilities in broader health solutions.

Which markets does Hila Pharma serve?

Hila Pharma serves global markets, including Israel, with business models targeting B2G, B2C, and B2B customers across healthcare providers, government, public transportation, schools, and industrial manufacturing.